PREVEC Trial: Prevention of Reperfusion damage associated with percutaneous coronary angioplasty following acute myocardial infarctio

Completed

• Conditions: Acute Myocardial Infarction; Circulatory System; Acute myocardial infarction, unspecified

• Registration Number: ISRCTN56034553
• Lead Sponsor: Scientific and Technological Development Fund (FONDECYT Fondo de Desarrollo Científico y Tecnológico) (Chile)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-01-28
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 132

Inclusion Criteria

1. Subjects may be of either sex and must be at least 18 years old
2. Subjects must have indication of primary percutaneous coronary angioplasty (PCA) as follows:
2.1. Angina or equivalent at least 120 min duration
2.2. Electrocardiogram (ECG) with STEMI that concerns more than 2 contiguous leads (>2mm)
3. Presentation within 12 h of symptoms onset
4. First myocardial infarction
5. Subject must be able and willing to sign informed consent

Exclusion Criteria

1. History of renal or hepatic insufficiency
2. History of renal lithiasis (oxalates)
3. History of heart failure (NYHA III, IV)
4. Cardiogenic shock
5. Any serious medical co-morbidity that determine life expectancy < 6 month
6. Current participation in any other clinical investigation
7. Pregnancy
8. Glucose 6-phosphate dehydrogenase deficiency

Study & Design

• Study Type: Interventional
• Study Design: Not specified